Zhibin Liao

Zhibin Liao

Auto-generated profile, based on publicly available information

Zhibin Liao

Division of Hepato‐Pancreato‐Biliary Surgery Tongji Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan Hubei China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 January 2022 in Biomarker Research
Verified
Journal Article
Open access
PDF file
XLXinxin Li
Xinxin Li
MHMengzhen Han
Mengzhen Han
HZHongwei Zhang
Hongwei Zhang
FLFurong Liu
Furong Liu
YPYonglong Pan
Yonglong Pan
BZBixiang Zhang
Bixiang Zhang
Zinc finger proteins are transcription factors with the finger domain, which plays a significant role in gene regulation. As the largest family of transcription factors in the human genome, zinc finger (ZNF) proteins are characterized by their different DNA binding motifs, such as C2H2 and Gag knuckle. Different kinds of zinc finger motifs exhibit a wide variety of biological functions. Zinc finger proteins have been reported in various diseases, especially in several cancers. Hepatocellular carcinoma (HCC) is the third leading cause of cancer-associated death worldwide, especially in China. Most of HCC patients have suffered from hepatitis B virus (HBV) and hepatitis C virus (HCV) injection for a long time. Although the surgical operation of HCC has been extremely developed, the prognosis of HCC is still very poor, and the underlying mechanisms in HCC tumorigenesis are still not completely understood. Here, we summarize multiple functions and recent research of zinc finger proteins in HCC tumorigenesis and progression. We also discuss the significance of zinc finger proteins in HCC diagnosis and prognostic evaluation.

7 October 2022 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
QHQibo Huang
Qibo Huang
JMJie Mo
Jie Mo
ZLZhibin Liao
Zhibin Liao
XCXiaoping Chen
Xiaoping Chen
BZBixiang Zhang
Bixiang Zhang
N6-methyladenosine (m6A) is a widely investigated RNA modification in studies on the “epigenetic regulation” of mRNAs that is ubiquitously present in eukaryotes. Abnormal changes in m6A levels are closely related to the regulation of RNA metabolism, heat shock stress, tumor occurrence, and development. m6A modifications are catalyzed by the m6A writer complex, which contains RNA methyltransferase-like 3 (METTL3), methyltransferase-like 14 (METTL14), Wilms tumor 1-associated protein (WTAP), and other proteins with methyltransferase (MTase) capability, such as RNA-binding motif protein 15 (RBM15), KIAA1429 and zinc finger CCCH-type containing 13 (ZC3H13). Although METTL3 is the main catalytic subunit, WTAP is a regulatory subunit whose function is to recruit the m6A methyltransferase complex to the target mRNA. Specifically, WTAP is required for the accumulation of METTL3 and METTL14 in nuclear speckles. In this paper, we briefly introduce the molecular mechanism of m6A modification. Then, we focus on WTAP, a component of the m6A methyltransferase complex, and introduce its structure, localization, and physiological functions. Finally, we describe its roles and mechanisms in cancer.

26 January 2024 in Cell Communication and Signaling
Verified
Journal Article
Open access
PDF file
CSChen Su
Chen Su
JMJie Mo
Jie Mo
SDShuilin Dong
Shuilin Dong
ZLZhibin Liao
Zhibin Liao
BZBixiang Zhang
Bixiang Zhang
PZPeng Zhu
Peng Zhu
Integrinβ-1 (ITGB1) is a crucial member of the transmembrane glycoprotein signaling receptor family and is also central to the integrin family. It forms heterodimers with other ligands, participates in intracellular signaling and controls a variety of cellular processes, such as angiogenesis and the growth of neurons; because of its role in bidirectional signaling regulation both inside and outside the membrane, ITGB1 must interact with a multitude of substances, so a variety of interfering factors can affect ITGB1 and lead to changes in its function. Over the past 20 years, many studies have confirmed a clear causal relationship between ITGB1 dysregulation and cancer development and progression in a wide range of benign diseases and solid tumor types, which may imply that ITGB1 is a prognostic biomarker and a therapeutic target for cancer treatment that warrants further investigation. This review summarizes the biological roles of ITGB1 in benign diseases and cancers, and compiles the current status of ITGB1 function and therapy in various aspects of tumorigenesis and progression. Finally, future research directions and application prospects of ITGB1 are suggested.

5 November 2022 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
HZHongwei Zhang
Hongwei Zhang
YLYachong Liu
Yachong Liu
WWWei Wang
Wei Wang
FLFurong Liu
Furong Liu
WWWeijian Wang
Weijian Wang
XCXiaoping Chen
Xiaoping Chen
As the most important RNA epigenetic regulation in eukaryotic cells, N6-metheyladenosine (m6A) modification has been demonstrated to play significant roles in cancer progression. However, this modification in long intergenic non-coding RNAs (lincRNAs) and the corresponding functions remain elusive. Here, we showed a lincRNALINC02551was downregulated by AlkB Homolog 5 (ALKBH5) overexpression in a m6A-dependent manner in hepatocellular carcinoma (HCC). Functionally,LINC02551was required for the growth and metastasis of HCC. Mechanistically,LINC02551, a bona fide m6A target of ALKBH5, acted as a molecular adaptor that blocked the combination between DDX24 and a E3 ligase TRIM27 to decrease the ubiquitination and subsequent degradation of DDX24, ultimately facilitating HCC growth and metastasis. Thus, ALKBH5-mediatedLINC02551m6A methylation was required for HCC growth and metastasis.

6 December 2021 in International Journal of Oncology
Verified
Journal Article
Open access
PDF file
ZLZhibin Liao
Zhibin Liao
HZHongwei Zhang
Hongwei Zhang
FPFan Pan
Fan Pan
QHQibo Huang
Qibo Huang
KDKeshuai Dong
Keshuai Dong
BZBixiang Zhang
Bixiang Zhang
Subsequently to the publication of the above article, and a Corrigendum that has already been published with the intention of showing the corrected version of Fig. 5 (DOI: 10.3892/ijo.2021.5213; published online on May 5, 2021), the authors have realized that only the data for Fig. 5C needed to be corrected with respect to the original figure published in the article, and there was no need to have presented replacement data for Fig. 5E in the previous Corrigendum. The further revised version of Fig. 5, featuring the corrected data for Fig. 5C, is shown on the next page. All the authors agree to this Corrigendum. Note that the revisions made to this figure do not adversely affect the results reported in the paper, or the conclusions stated therein. The authors regret that Fig. 5 was not presented in its finally revised form in the previous Corrigendum, and offer their apologies to the Editor and to the readers of the Journal. [the original article was published in International Journal of Oncology 54: 479‑490, 2019; DOI: 10.3892/ijo.2018.4659]

13 January 2023 in Hepatology
Verified
Journal Article
Open access
FLFurong Liu
Furong Liu
ZLZhibin Liao
Zhibin Liao
LQLu Qin
Lu Qin
ZZZe Zhang
Ze Zhang
QZQiaofeng Zhang
Qiaofeng Zhang
ZZZhan-Guo Zhang
Zhan-Guo Zhang
Background and Aims: HCC is a highly heterogeneous disease that is caused largely by genomic copy number variations. Herein, the mechanistic and therapeutically targeted role of vacuolar protein sorting 72 homologue (VPS72), a novel copy number variation cis-driven gained gene identified by genome-wide copy number variation and transcriptome analyses in HCC, is not well understood. Approach and Results: First, overexpression of VPS72 enhanced the initiation and progression of HCC in vitro and in vivo. Mechanistically, VPS72 interacted with the oncoproteins MYC and actin-like 6A (ACTL6A) and promoted the formation of the ACTL6A/MYC complex. Furthermore, ACTL6A regulated VPS72 protein stability by weakening the interaction between tripartite motif containing 21 (TRIM21) and VPS72. Thus, the interaction between VPS72 and ACTL6A enhanced the affinity of MYC for its target gene promoters and promoted their transcription, thereby contributing to HCC progression, which was inhibited by adeno-associated virus serotype 8 (AAV8)-mediated short hairpin RNA (shRNA) against VPS72. Conclusions: This study reveals the molecular mechanism of ACTL6A/VPS72/MYC in HCC, providing a theoretical basis and therapeutic target for this malignancy.